System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jieyu Xing is an expert in Oncology at Beijing Friendship Hospital (China). Jieyu Xing has authored 12 publications, the most recent in 2023. SLR score: 25 (community average: 125). How the SLR is computed.

LeadR Profile

Jieyu Xing Beijing Friendship Hospital China
25 ScienceLeadR Reputation 25

Unlock

Register Login
Network Map

Oncology

Subspecialties:

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2016 - 2023
Source: PubMed

Beijing Friendship Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 12

Citations

Citations: 218 1st author: 3 Last author: 0 Unique author: 0

Main journals

AMB Express 1
Aliment Pharmacol Ther 1
Anaesth Rep 1
Clin Transl Oncol 1
Drug Des Devel Ther 1

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Clinicopathological characteristics, surgical treatments, and oncological outcomes of localized primary unifocal urothelial carcinoma involving the ureterovesical junction.
PMID 37847324 — kidney diseases, urology, pain, ureter, neoplasms, sex, therapeutics, abdominal pain		Int Urol Nephrol20230
Use of a urinary catheter as a guidewire to facilitate safe nasotracheal intubation following iatrogenic retropharyngeal perforation.
PMID 36504729 — intubation, mouth, urinary catheters		Anaesth Rep20222
Association between Preoperative hs-crp/Albumin Ratio and Postoperative sirs in Elderly Patients: A Retrospective Observational Cohort Study.
PMID 35450991 — anesthesia, general, diabetes mellitus, aging, c-reactive protein, cohort studies, hospital mortality, aged		J Nutr Health Aging202220
A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities.
PMID 30214153 — cytokines, drug therapy, immunotherapy, cells, neoplasms, t-lymphocytes, interleukin-15		Drug Des Devel Ther201816
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity.
PMID 30059039 — biological science disciplines, cells, liver neoplasms, single-domain antibodies		J Vis Exp20187

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS